PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read sequencer, into a compact, lower-throughput benchtop platform. Offering exceptional data accuracy... Read more

Bruker Announces Formation of New Bruker Spatial Biology Division

Bruker Spatial Biology Offers the Widest Range of Industry-leading Multiomic Spatial Biology Platforms to Scientists Globally BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination three entities: the... Read more

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore

SINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Institute of Singapore (A*STAR GIS) in Singapore. This new facility, located on... Read more

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 100,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 50,000 shares... Read more

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies. New technology... Read more

Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D. WASHINGTON, June 5, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator,... Read more

Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

timsTOF Ultra 2 enables significant further improvements in deep, high-fidelity 4D-Proteomics™ of mammalian cells, cancer cell lines, or tissue biopsies With sensitivity to measure >1000 proteins on just 25 pg, the timsTOF Ultra 2 opens new cell and disease biology research windows into PBMCs, small immune cells, bacterial cells, or subcellular organelle proteomics timsTOF Ultra... Read more

Bruker Launches Transformative neofleX ™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications

neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam 3D laser neofleX and MALDI HiPLEX-IHC technology enable protein tissue imaging Multiomics MSI correlation of targeted proteins with glycans, metabolites, lipids, endogenous peptides, and now also mid-plex mRNA/DNA-ISH More insights per pixel... Read more